Charles Schwab Investment Management Inc. Buys 127,467 Shares of Precigen, Inc. (NASDAQ:PGEN)

Charles Schwab Investment Management Inc. lifted its stake in shares of Precigen, Inc. (NASDAQ:PGEN) by 11.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,222,850 shares of the biotechnology company’s stock after acquiring an additional 127,467 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.48% of Precigen worth $1,158,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Traphagen Investment Advisors LLC bought a new position in Precigen during the 3rd quarter worth approximately $29,000. SG Americas Securities LLC increased its position in shares of Precigen by 44.2% during the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after buying an additional 13,823 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Precigen by 86.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after buying an additional 25,681 shares during the period. AQR Capital Management LLC raised its stake in Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after buying an additional 18,097 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Precigen by 40.7% in the second quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 16,486 shares during the period. 33.51% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Precigen in a report on Friday, November 15th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.00.

Precigen Stock Up 2.5 %

Precigen stock opened at $0.69 on Wednesday. The company has a market capitalization of $202.14 million, a PE ratio of -1.25 and a beta of 1.71. Precigen, Inc. has a 12-month low of $0.65 and a 12-month high of $1.93. The firm’s fifty day moving average is $0.86 and its 200 day moving average is $1.16.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.